ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 750

Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort

Elena Baldissera1, Alessandro Tomelleri 1, Silvia Sartorelli 2, Corrado Campochiaro 3 and Lorenzo Dagna 1, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, 2Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: takayasu arteritis and comorbidity

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Takayasu arteritis (TAK) is an inflammatory disease which primarily affects large vessels. However, as a systemic disease, the spectrum of its manifestations is not limited to the arterial wall.

Methods: Data records of TAK patients diagnosed according to the 1990 ACR criteria and followed-up at our Large Vessel Vasculitis Clinic were reviewed. Any significant inflammatory/autoimmune comorbidity and family history for inflammatory/autoimmune disease were considered. For each comorbidity, temporal correlation with TAK diagnosis was assessed. Need for biological therapy for TAK control, as an indirect measure of TAK aggressiveness, was evaluated. Non-parametric statistic tests were used.

Results: In our cohort of 128 TAK patients, 46 patients (35.9%) were identified as having an inflammatory/autoimmune comorbidity, for a total of 64 comorbidities (14 patients experienced >1 comorbidity). Comorbidities were classified into 6 categories: systemic inflammatory diseases (11 patients, 14.3%); gastro-intestinal (6 patients, 7.8%), articular (7 patients, 9.1%), ocular (13 patients, 16.9%) and muco-cutaneous (25 patients, 32.5%) involvement; miscellaneous (autoimmune hepatitis, retroperitoneal fibrosis). In 33 cases (51.6%) the comorbidity onset preceded, in 25 (39%) followed and in 6 (9.4%) was synchronous with TAK diagnosis (Table 1). In 25 patients (54.3%) use of a biological therapy to control TAK activity was needed (versus 35.4% in TAK patients without comorbidities, p = 0.042). Having a comorbidity increased the risk for the introduction of a biologic therapy, odds ratio=2.176 (1.042-4.541). Of the 128 TAK patients, 17 (13.3%) had a positive family history for inflammatory or autoimmune diseases (8 psoriasis, 5 rheumatoid arthritis, 3 inflammatory bowel disease, 1 sarcoidosis).

Conclusion: In TAK patients, extravascular involvement is a common finding and usually precedes the vascular involvement (the only significant exception is represented by inflammatory arthritis). Inflammatory and autoimmune extravascular comorbidities seem to be associated with a significant higher burden of vascular inflammation, as inferred by the higher rate of biological therapies use in these TAK patients.


Table 1

Prevalence and characteristics of inflammatory/autoimmune extravascular comorbidities in a cohort of 128 patients with Takayasu arteritis -TAK-, temporal correlation with TAK diagnosis, and need for biological therapy.


Disclosure: E. Baldissera, Sobi, 8, Sanofi, 5, Roche, 8, Pfizer, 8, Novartis, 8, Abbvie, 8, Alfa-sigma, 8; A. Tomelleri, None; S. Sartorelli, None; C. Campochiaro, GSK, 8, GSK, SOBI, Pfizer, 5, 8, Pfizer, 8, SOBI, 5; L. Dagna, Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Sanofi-Genzyme, and SOBI., 5, 8.

To cite this abstract in AMA style:

Baldissera E, Tomelleri A, Sartorelli S, Campochiaro C, Dagna L. Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/extravascular-inflammatory-manifestations-of-takayasu-arteritis-in-a-monocentric-cohort/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extravascular-inflammatory-manifestations-of-takayasu-arteritis-in-a-monocentric-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.